The Future of Clay Siegall Seattle Genetics

Posted on

Cancer is a disease that has plagued most economies even for those of developed countries like the USA. One company that stands tall and is determined to change the cancer narrative completely is Seattle Genetics. Headquarters in Cascade business park, the clustered buildings that hosts Seattle Genetics does not communicate anything that would suggest the involvement of this giant company to the deadly disease; however as you get inside the building you will meet a triangular sculpture green in color symbolizing the human antibody.

Since its establishment in 1998 Seattle Genetics has been involved with research works, manipulation and manufacturing of drugs that help with cancer therapy. The working principle behind Seattle Genetics has always been connecting the drugs with the antibodies that reside within the body. Through the drugs the company has been able to treat cancer by destroying the cancerous cells from inside.

Despite the fact that this strategy may look simple, in reality it has been able to hurl Seattle Genetics to the top charts in the market. Currently Seattle Genetics boasts of a market value of over $ 10 billion and an employee population of 900. Thanks to this, the company now ranks among the few companies with the possibilities of changing from biotech to pharma. In order to achieve this the company is required to invest heavily in research and development and also increase its employee base with 200 employees. The Seattle Genetics community is one that is rallying behind the promotion of this company to a pharmaceutical company as it will help them have a partner they can count on to mitigate the cancer plague in their community.

About Clay Siegall

Clay Siegall is a renowned biotech who has helped found Seattle Genetics the biotechnology firm that specializes in research and development of therapeutic cancer drugs. Dr. Clay Siegall is quite reputable, in addition to contributing to the health sector through his company, Clay has also helped develop and manufacture a number of drugs that have been approved by FDA.

Dr. Clay is a graduate of George Washington University where he studied his bachelor’s degree in genetics before advancing it with a Phd. In addition to being a healthcare provider Clay Siegall is also a distinguished leader. His leadership role in Seattle Genetics is quite commendable as he has helped the company make a lot of progress. To prove his prowess, Dr. Clay has been awarded are recommended on multiple account including the 2012’s Pacific Northwest Ernst & Young Entrepreneur of the Year.


Omar Boraie Makes Large Donation to Cancer Research

Posted on

It was reported by Newswise in this article – http://newswise.com/articles/omar-boraie-chair-in-genomic-science-established-at-rutgers-cancer-institute – that Omar Boraie made a large donation to the Rutgers Cancer Institute of New Jersey. With the donation, the Omar Boraie Chair in Genomic Science was created at the institute. An endowed chair is considered a firm commitment by a university to dedicate themselves to a first-class academic discipline as well as guarantee their continued support of the program in the future. The donation that Omar Boraie pledged was $1.5 million that will be matched to be $3 million in total for the chair. In a statement of Director of Rutgers Cancer Institute, Dr. Robert DiPaola, said that Omar Boraie had been a long term supporter of the institute and that they were thankful for his generosity.

The specialization that Boraie supported was genomic science and precision medicine. This field as explained by patch.com, is changing how researchers approach cancer diagnoses and the treatments they prescribe. This is a new field that investigates and treats cancerous tumors on the genetic level. The field came to national prominence when former President Obama announced the start of a Precision Medicine Initiative on a national scale in the effort to find a cure for cancer as well as other diseases. Rutgers Cancer Institue was one of the first research facilities in the United States to use the precision medicine approach on genomic sequencing in patient care.

According to NJ Biz, the person named to the chair was Shridar Ganesan, MD, PhD. He is an Associate Director for Translational Science. He has also been in charge of the precision medicine trials at the institute as well as an Associate Professor of Medicine and Pharmacology at Rutgers Robert Wood Johnson Medical School. He has been internationally recognized top academic researcher by his peers. In a statement about his appointment, he commented that cancer is not a single disease but rather a collection of them. He said that the donation by Boraie will help advance clinical research give new hope to patients and their families.

Reference: http://www.nytimes.com/2005/03/06/realestate/at-two-extremes-of-a-housing-market.html